South Korea Extends Approval for ALS Stem Cell Therapy Neuronata-R

While the treatment did not meet statistical significance across the entire study population during the ALSUMMIT trial, it demonstrated clear efficacy within a subgroup of slow progressors. These patients showed improvement in the Combined Assessment of Function and Survival and the ALS Functional Rating Scale-Revised. Notably, the therapy also reduced neurofilament light chain levels, a biomarker increasingly relied upon by regulators to gauge neuronal damage.

CorestemChemon is currently preparing to restart manufacturing, with full-scale production expected by early next year. Beyond domestic operations, the company is expanding its footprint in the United States. It recently joined the Piedmont Triad Regenerative Medicine Engine, an initiative supported by the National Science Foundation, and is coordinating with the Wake Forest Institute for Regenerative Medicine. Management intends to seek a Type C meeting with the FDA to advance a Biologics License Application for the U.S. market in 2027. Neuronata-R, which uses a patient's own bone marrow-derived mesenchymal stem cells to secrete neuroprotective factors, has already been administered to over 400 individuals in South Korea.